repuls® LLLT has proven to be efficient in the field of plastic, esthetic and reconstructive surgery, particularly to support the therapy of chronic soft-tissue defects as well as to improve the wound healing after extensive reconstructive surgery such as abdominoplasty/lower body lift, breast surgery and various kinds of flaps. Patients suffering from chronic wounds or wound healing disorders can benefit from repuls® LLLT.
Frequently there is also a colonisation or infection with germs impeding the healing, and many of these patients present with relevant co-morbidities such as diabetes or reduced blood circulation.
repuls® LLLT can optimize the healing under adverse conditions and improve the scar formation.
Treatment of burn victims is another challenging task in plastic surgery. Large wounds are typically at
high risk regarding infections. With repuls® LLLT the surgical treatment can be ideally complemented.
repuls ist ein CE-zertifiziertes Produkt made in Austria, das nach den neuesten Richtlinien der europäischen Medizinprodukte-Verordnung zugelassen ist - Zertifikat MDD-194. Das bedeutet nachgewiesene Wirksamkeit und optimale Sicherheit. Repuls betreibt ein zertifiziertes Qualitätsmanagementsystem nach ISO-13485:2016.